Figure 1. Enrollment of Patients for Cohort 1 of the KEYNOTE-059 Study.

Eligible patients were 18 years or older; had histologically or cytologically confirmed recurrent or metastatic gastric or gastroesophageal cancer; and had disease progression after 2 or more prior chemotherapy regimens that included a fluoropyrimidine and a platinum doublet.